Securities code: 600518 securities abbreviation: Kangmei Pharmaceutical Co.Ltd(600518) No.: lin2021-117 bond Code: 122354 bond abbreviation: 15 Kangmei bond
Bond Code: 143730 bond abbreviation: 18 Kangmei 01
Bond Code: 143842 bond abbreviation: 18 Kangmei 04
Preferred stock code: 360006 preferred stock abbreviation: kangmeiyou 1
Kangmei Pharmaceutical Co.Ltd(600518) about deferred disclosure
The board of directors and all directors of the company guarantee that the contents of this announcement are free from any false records, misleading statements or major omissions, and bear individual and joint responsibilities for the authenticity, accuracy and completeness of its contents. Kangmei Pharmaceutical Co.Ltd(600518) (hereinafter referred to as “the company”) held the seventh interim meeting of the eighth board of directors in 2021 and the third interim meeting of the eighth board of supervisors in 2021 respectively on October 28, 2021, deliberated and adopted the proposal on correction and retroactive adjustment of accounting errors in the previous period. The difference between the company’s appraisal value and book value is 3331322698.82 yuan, and it is impossible to determine the specific time point of impairment. Therefore, in order to objectively reflect the company’s asset status, the difference between the appraisal value and book value is retroactively adjusted to the beginning of 2021, and the first quarter of 2021 and the semi annual report of 2021 are corrected. According to the rules for the preparation of information disclosure of companies offering securities to the public No. 19 – correction and related disclosure of financial information (revised in 2018), The company shall disclose the special assurance report issued by the accounting firm on this correction within two months from the date of disclosure of the suggestive announcement of Kangmei pharmaceutical on correction and retrospective adjustment of previous accounting errors (Announcement No.: pro 2021-079). See the relevant announcement disclosed by the company on October 30, 2021 for the above contents.
On December 17, 2021, the company held the third extraordinary general meeting of shareholders in 2021, deliberated and approved the proposal on changing accounting affairs, and appointed Tianzhi international accounting firm (special general partnership) as the company’s financial audit institution in 2021. Since the annual audit accountant still needs to fully understand the above matters, the company applies to disclose the special assurance report on early accounting error correction and retrospective adjustment no later than April 30, 2022.
The information disclosure media designated by the company are China Securities News, Shanghai Securities News, securities times, securities daily and the website of Shanghai Stock Exchange (www.sse. Com.. CN.), All information of the company shall be subject to the information disclosed in the above designated media.
Please pay attention to the company’s announcement and pay attention to investment risks.
It is hereby announced.
Kangmei Pharmaceutical Co.Ltd(600518) board of directors
December 31, 2001
